Get the Stockscreener App
36.44
4.05%
-1.54
First Tracks Biotherapeutics Inc stock is traded at $36.44, with a volume of 619.86K.
It is down -4.05% in the last 24 hours and down -22.05% over the past month.
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
See More
Previous Close:
$37.98
Open:
$38.08
24h Volume:
619.86K
Relative Volume:
0.83
Market Cap:
$1.30B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-9.94%
1M Performance:
-22.05%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$35.49
$38.30
1-Week Range:
$35.49
$43.78
52-Week Range:
$14.72
$49.91
First Tracks Biotherapeutics Inc Stock (TRAX) Company Profile
Name
First Tracks Biotherapeutics Inc
Sector
Industry
Phone
212-373-3000
Address
10770 WATERIDGE CIRCLE, SAN DIEGO
Compare TRAX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAX
First Tracks Biotherapeutics Inc
|
36.44 | 1.36B | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.42B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 81.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.56B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 54.54B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.59B | 742.00K | -1.37B | -1.07B | -7.0731 |
First Tracks Biotherapeutics Inc Stock (TRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Initiated | Leerink Partners | Outperform |
| Apr-24-26 | Initiated | Wedbush | Outperform |
| Apr-23-26 | Initiated | JP Morgan | Overweight |
| Apr-22-26 | Initiated | Barclays | Overweight |
| Apr-21-26 | Initiated | UBS | Buy |
First Tracks Biotherapeutics Inc Stock (TRAX) Latest News
First Tracks Biotherapeutics at wells fargo healthcare conference: data loom By Investing.com - Investing.com South Africa
First Tracks Biotherapeutics Insider Ware J. Anthony Sells 39,265 Shares at $44.78 Following Option Exercise - kalkinemedia.com
TRAX Price Today: First Tracks Biotherapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
First Tracks Biotherapeutics Director Sold Shares Worth Over $1.7M - TradingView
First Tracks Biotherapeutics (TRAX) director sells shares after option exercise - Stock Titan
H.C. Wainwright Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $57 - Moomoo
TRAX Reiterates by First Tracks -- Price Target Maintained at $5 - GuruFocus
Long term debt to total assets ratio of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Which stocks are gapping on Wednesday? - ChartMill
Cash flow from operating activities of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
EBIT per share of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Total debt of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
After tax other income/expense of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
First Tracks Biotherapeutics Announces Participation in September Investor Conferences - Yahoo Finance
Non-controlling/minority interest of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Total liabilities of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Taxes of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Diluted shares outstanding of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Total operating expenses of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Diluted earnings per share (diluted EPS) of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
First Tracks Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:TRAX - TradingView
Total revenue of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - tradingview.com
Dilution adjustment of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Price to cash flow ratio of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
CapEx per share of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Number of shareholders of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Enterprise value to EBITDA forward of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - tradingview.com
Net debt of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Gross profit of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
EBIT of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Net current asset value per share of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Free cash flow of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Total liabilities & shareholders' equities of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Non-operating income (total) of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Enterprise value to EBITDA ratio of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
EBITDA per share of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Enterprise value to EBIT forward of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Operating expenses (excl. COGS) of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Discontinued operations of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
Diluted net income available to common stockholders of First Tracks Biotherapeutics, Inc. – NASDAQ:TRAX - TradingView
AnaptysBio, Inc. (ANAB) Earnings Preview: The First Full Royalty-Model Quarter Matters More Than the Headline EPS - AlphaStreet
J.P. Morgan Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Raises Target Price to $65 - Moomoo
Piper Sandler Maintains First Tracks Biotherapeutics(TRAX.US) With Buy Rating, Maintains Target Price $95 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
First Tracks Biotherapeutics CBO Benjamin Stone Receives 60,492 Performance Stock Units - Kalkine Media
First Tracks Biotherapeutics' CMO Paul F. Lizzul Earns 60,492 Performance Stock Units Following Certified Milestones - Kalkine Media
First Tracks Biotherapeutics CEO Daniel Faga Awarded 193,575 Performance Stock Units - Kalkine Media
First Tracks (TRAX) insider records new share trades - Stock Titan
First Tracks Biotherapeutics (TRAX) insider updates holdings - Stock Titan
First Tracks Biotherapeutics (TRAX) insider logs trades - Stock Titan
FIRST TRACKS BIOTHERAPEUTICS INC : JP MORGAN RAISES TARGET PRICE TO $65 FROM $30 - Moomoo
First Tracks Biotherapeutics Inc Stock (TRAX) Financials Data
There is no financial data for First Tracks Biotherapeutics Inc (TRAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.24%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):